Vertex Pharmaceuticals Gross 
Unrealized 
Gains decreased by 61.9% to $16.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.0%, from $32.50M to $16.90M. Over 5 years (FY 2020 to FY 2025), Gross 
Unrealized 
Gains shows a downward trend with a -21.1% CAGR.
other_debtand_equity_securities_unrealized_gain| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $102.78M | $150.34M | $167.10M | $92.20M | $12.30M | $29.20M | $31.10M | $52.60M | $0.00 | $600.00K | $15.90M | $6.20M | $3.70M | $66.80M | $22.80M | $32.50M | $41.00M | $45.10M | $44.30M | $16.90M |
| QoQ Change | — | +46.3% | +11.1% | -44.8% | -86.7% | +137.4% | +6.5% | +69.1% | -100.0% | — | >999% | -61.0% | -40.3% | >999% | -65.9% | +42.5% | +26.2% | +10.0% | -1.8% | -61.9% |
| YoY Change | — | — | — | — | -88.0% | -80.6% | -81.4% | -43.0% | -100.0% | -97.9% | -48.9% | -88.2% | — | >999% | +43.4% | +424.2% | >999% | -32.5% | +94.3% | -48.0% |